DT&CRO CO., Ltd. (KOSDAQ:383930)
South Korea · Delayed Price · Currency is KRW 3,360.00
+105.00 (3.23%)
At close: Apr 2, 2026
DT&CRO CO. Revenue
In the year 2025, DT&CRO CO. had annual revenue of 47.75B KRW with 32.74% growth. DT&CRO CO. had revenue of 15.01B in the quarter ending December 31, 2025, with 29.17% growth.
Revenue
47.75B
Revenue Growth
+32.74%
P/S Ratio
0.90
Revenue / Employee
n/a
Employees
n/a
Market Cap
42.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 47.75B | 11.78B | 32.74% |
| Dec 31, 2024 | 35.97B | 9.38B | 35.30% |
| Dec 31, 2023 | 26.59B | -17.42B | -39.59% |
| Dec 31, 2022 | 44.01B | 11.26B | 34.38% |
| Dec 31, 2021 | 32.75B | 12.66B | 63.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HLB bioStep | 74.05B |
| C&R Research | 64.98B |
| DreamCIS | 62.06B |
| WOOJUNG BIO | 37.12B |
| BioInfra | 23.15B |
| P&K Skin Research Center | 22.13B |
| Penetrium Bioscience | 9.74B |
| Curachem | 6.02B |